A randomized phase II open label multi-institution study of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) in the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC).

被引：0
|
作者：
Thomas, Melanie B.
Garrett-Mayer, Elizabeth
Anis, Munazza
Anderton, Kate Robertson
Bentz, Tricia A.
Adelman, Andie Ray
Brisendine, Alan
Duddalwar, Vinay
Weiss, Geoffrey R.
Siegel, Abby B.
Bendell, Johanna C.
Baron, Ari David
El-Khoueiry, Anthony B.
机构：
[1] Med Univ S Carolina, Charleston, SC 29425 USA
[2] Hollings Canc Ctr Med Unit, Charleston, SC USA
[3] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
[4] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Univ Virginia, Charlottesville, VA USA
[6] Columbia Univ, New York, NY USA
[7] PLLC, Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[8] Pacif Hematol Oncol Assoc, San Francisco, CA USA
[9] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.337
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
337
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress
    Qin, S.
    Finn, R. S.
    Kudo, M.
    Meyer, T.
    Vogel, A.
    Ducreux, M. P.
    Macarulla, T. M.
    Tomasello, G.
    Boisserie, F.
    Hou, J.
    Li, C.
    Song, J.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)
    Raoul, J. L.
    Finn, R. S.
    Kang, Y. K.
    Park, J. W.
    Harris, R.
    Coric, V.
    Donica, M.
    Walters, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Ramucirumab (RAM) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) Following First-Line Therapy with Sorafenib: Analyses from the Randomized Phase III REACH Study
    Barone, C.
    Brandi, G.
    Daniele, B.
    Villa, E.
    Leo, S.
    Di Fabio, F.
    Aprile, G.
    Colombo, M.
    Sobrero, A.
    Giannelli, G.
    Porta, C.
    Cabibbo, G.
    Zhu, A.
    Blanc, J.
    Okusaka, T.
    Chau, I.
    Abada, P.
    Yang, L.
    Pastorelli, D.
    ANNALS OF ONCOLOGY, 2015, 26 : 91 - 91
  • [24] Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore
    Chee, Cheng Ean
    Khara, Jasmeet Singh
    Cheong, John
    Fong, Jek
    Sivanesan, Sivabalan
    Choy, Jian Yi
    Hu, Meibo
    Viswambaram, Amrita
    Toh, Han Chong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (05) : 631 - 641
  • [25] A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC)
    Harding, James J.
    Abou-Alfa, Ghassan K.
    Shi, Yuankai
    Whang-Peng, Jacqueline
    Yuen, Man Fung
    Saif, Wasif M.
    Tian, Aiping
    Gu, Shanzhi
    Lam, Wing
    Liu, Shwu-Huey
    Cheng, Yung-Chi
    Chu, Edward
    Yen, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [26] Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC)
    Cheng, Ann-Lii
    Thongprasert, Sumitra
    Lim, Ho Yeong
    Sukeepaisarnjaroen, Wattana
    Yang, Tsai-Sheng
    Wu, Cheng-Chung
    Chao, Yee
    Chan, Stephen Lam
    Kudo, Masatoshi
    Ikeda, Masafumi
    Kang, Yoon-Koo
    Pan, Hongming
    Numata, Kazushi
    Han, Guohong
    Balsara, Binaifer
    Zhang, Yong
    Rodriguez, Ana-Maria
    Zhang, Yi
    Wang, Yongyu
    Poon, Ronnie Tung-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [27] A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC)
    Shen, Y.
    Hsu, C.
    Hsu, C.
    Lin, Z.
    Chen, P.
    Shao, Y.
    Huang, T.
    Ding, Y.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study
    Hao, Chunyi
    Du, Chengyou
    Peng, Baogang
    Zhang, Wu
    Shan, Yunfeng
    Lv, Ang
    Wu, Jianhui
    Shang, Changzhen
    Luo, Xuan
    Wei, Jinxing
    Xiao, Heng
    Qiu, Jianguo
    Hua, Yunpeng
    Shen, Shunli
    Wang, Ting
    Dai, Shengjie
    Chen, Xiang
    Yan, Shican
    Hao, Chunyi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [29] An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma
    Bi, Feng
    Zhang, Yan-Qiao
    Gu, Shanzhi
    Guo, Yabing
    Xu, Zhongyuan
    Ying, Hao
    Da, Mingxu
    Liu, Chaoying
    Pan, Yaozhen
    Huang, Yao
    Chen, Zhiyu
    Wang, Zheng
    Wu, Jianbing
    Weng, Shangeng
    Wang, Yanjun
    Zhao, Jun
    Yu, Xiaokui
    Li, Hui
    Xue, Shilin
    Kang, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
    Lin, Zhong-Zhe
    Chen, Bang-Bin
    Hung, Yi-Ping
    Huang, Po-Hsiang
    Shen, Ying-Chun
    Shao, Yu-Yun
    Hsu, Chih-Hung
    Cheng, Ann-Lii
    Lee, Rheun-Chuan
    Chao, Yee
    Hsu, Chiun
    ONCOLOGIST, 2020, 25 (09): : E1280 - E1285
12345